AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Medicines Agency's (EMA) Committee for ...

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top ...

The FDA granted priority review for Datroway based on results from the TROPION-Breast02 Phase III trial.

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to ...

Why Daiichi Sankyo Company (TSE:4568) is on investors’ radar today Daiichi Sankyo Company (TSE:4568) has attracted attention after recent share moves, with a 1.4% gain over the past day and a 5.0% ...

The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's ...

"Eddie” Viriyahboubpha: Since the launch of your new cancer treatment in your fiscal year 2019, Daiichi Sankyo’s global ...

Japan’s first domestically produced vaccine for the virus that causes COVID-19 has been cleared for regulatory approval.

Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo FRANKFURT (Reuters) - Daiichi Sankyo said on Friday it would invest about 1 billion euros ($1.07 billion) to expand a site near ...